We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

The Challenges of Laryngeal Preservation—Is It the Systemic Agent or the Proper Sequence of Therapy?

Nabil F. Saba, MD1; Dong M. Shin, MD1
[+] Author Affiliations
1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia
JAMA Otolaryngol Head Neck Surg. 2016;142(9):849-850. doi:10.1001/jamaoto.2016.1229.
Text Size: A A A
Published online


During the last 20 years, laryngeal preservation (LP) has been the cornerstone of advances in larynx cancer therapy. Since the early Veterans Affairs laryngeal study,1 neoadjuvant therapy has been believed to achieve organ preservation without compromising survival in most patients (66%) with locally advanced laryngeal cancer. This finding was further supported by the European Organization for Research and Treatment of Cancer larynx preservation study.2 Thereafter, the Radiation Therapy Oncology Group (RTOG) 91-11 trial found a higher rate of LP after concurrent platinum-based chemoradiotherapy (hazard ratio, 0.46; 95% CI, 0.30-0.71), resulting in the adoption of this approach as the modality of choice for LP, at least in the United States.3 With longer follow-up, the end point of laryngeal-free survival was improved for the concomitant and sequential approaches, whereas radiotherapy alone was clearly inferior.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
[Pneumomediastinum - a case report]. Pol Merkur Lekarski 2016;41(241):93-6.
[Pneumomediastinum - a case report]. Pol Merkur Lekarski 2016;41(242):93-6.